UniProtKB/Swiss-Prot O43914: Variant p.Ile84Val

TYRO protein tyrosine kinase-binding protein
Gene: TYROBP
Feedback?

Variant information Variant position:

84 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Isoleucine (I) to Valine (V) at position 84 (I84V, p.Ile84Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Found in patients with early-onset Alzheimer disease; uncertain significance. Any additional useful information about the variant.

Sequence information Variant position:

84 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

113 The length of the canonical sequence.
Location on the sequence:

LGRLVPRGRGAAEAATRKQR I TETESPYQELQGQRSDVYSD The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LGRLVPRGRGAAEAATRKQRITETESPYQELQGQRSDVYSD

Rhesus macaque                LGRLVPRGRGAAEAATRKQRITETESPYQELQGQRSDVYSD

Chimpanzee                    LGRLVHRGRGAAEAATRKQRITETESPYQELQGQRSDVYSD

Mouse                         LGRLVSRGQGTAE-GTRKQHIAETESPYQELQGQRPEVYSD

Rat                           LGRLVSRGRGTAD-GTRKQHMAETESPYQELQGQRPEVYSD

Pig                           LGRLVPRTRGAVD-VTRKQHIAETESAYQELQGQRSDVYSD

Bovine                        LGRLVPRGRGATE-VTRKQHIPETESPYQELQGQRTDVYSD

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	22 – 113	TYRO protein tyrosine kinase-binding protein
Topological domain	62 – 113	Cytoplasmic
Domain	80 – 108	ITAM
Region	75 – 113	Disordered
Modified residue	91 – 91	Phosphotyrosine
Modified residue	102 – 102	Phosphotyrosine
Alternative sequence	77 – 77	Missing. In isoform 2.

Literature citations
TYROBP genetic variants in early-onset Alzheimer's disease.
Pottier C.; Ravenscroft T.A.; Brown P.H.; Finch N.A.; Baker M.; Parsons M.; Asmann Y.W.; Ren Y.; Christopher E.; Levitch D.; van Blitterswijk M.; Cruchaga C.; Campion D.; Nicolas G.; Richard A.C.; Guerreiro R.; Bras J.T.; Zuchner S.; Gonzalez M.A.; Bu G.; Younkin S.; Knopman D.S.; Josephs K.A.; Parisi J.E.; Petersen R.C.; Ertekin-Taner N.; Graff-Radford N.R.; Boeve B.F.; Dickson D.W.; Rademakers R.;
Neurobiol. Aging 48:222.E9-222.E15(2016)
Cited for: VARIANTS GLU-2; CYS-23; ALA-47; PRO-ALA-ASP-GLY-ARG-LEU-VAL-LEU-GLY-ASP-ARG-ASP-GLY-ARG-50 INS; LEU-55; TRP-80; VAL-84 AND LEU-89;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.